Luspatercept - aamt | Aplastic Anemia & MDS International Foundation Return to top.


Brand name: 
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)

REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who have been failed by an erythropoiesis-stimulating agent (ESA) or are unlikely to respond to an ESA, and are requiring transfusions of 2 or more red blood cell (RBC) units over 8 weeks. The drug is thought to work by decreasing the level of certain proteins that inhibit growth of red blood cells in the bone marrow. The approval is specifically for patients with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). The benefit of luspatercept-aamt in other subtypes of MDS is unclear, and the approval does not extend to other MDS subtypes.

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Share with